Hepatobiliary Neoplasia SIG: New Therapies in HCC: Mechanisms of Action and Indications

4.5 (2 votes)

Recorded On: 11/11/2018

This program will describe the molecular mechanisms and rationale for novel systemic therapy agents targeting signaling pathways and immune mechanisms that have been recently approved for the treatment of hepatocellular carcinoma. The program will also cover the roles of new agents in the current AASLD guidelines for treatment of hepatocellular carcinoma.

Jessica Zucman-Rossi

Augusto Villanueva

Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain). In 2005, he joined the Division of Liver Diseases at Mount Sinai Hospital (New York) as a research fellow and was involved in different translational research projects focused on the molecular pathogenesis of hepatocellular carcinoma (HCC). In 2008, he obtained his PhD and received the Sheila Sherlock Fellowship from EASL to join the Liver Cancer Translational Research Laboratory of the BCLC Group, Barcelona (Spain). In 2010, he became the Scientific Manager of the HEPTROMIC consortium, a research initiative funded by the European Commission aimed at identifying genomic prognostic predictors and oncogenic drivers in HCC.

In 2013, he joined the Institute of Liver Studies at King’s College (London), as a Senior Lecturer and Consultant Hepatologist where he served as co-leader of the HCC Clinic and Multidisciplinary Tumor Board. In 2014, he started his position at the Icahn School of Medicine at Mount Sinai with the goal of developing novel minimally invasive biomarkers using liquid biopsy and studying the impact of intratumor heterogeneity in HCC. He has more than 100 publications (10,000 citations, H-index 44) including articles in N Engl J MedNat GenetNat BiotechGastroenterology, HEPATOLOGY, J HepatolJ Clin InvestOncogene, etc. He wrote more than fifteen book chapters and edited a book on resistance to targeted therapies in HCC. He served as Associate Editor for J Hepatol (2014-2019) and Liver Cancer (2012-present).

Josep Llovet

Josep M. Llovet, MD, PhD is Professor of Medicine – Hepatic Oncology at University of Barcelona, Professor of Research-ICREA in the Liver Unit, IDIBAPS-Hospital Clínic of Barcelona and Director of the Liver Cancer Program and Full Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York and Director.  Professor Llovet obtained his degree in Medicine and Surgery from the University of Barcelona in 1986 and his PhD from the Autonomous University of Barcelona in 1995. 

Professor Llovet has been President, Secretary and Founder of the International Liver Cancer Association (ILCA) and Chairman of the European Clinical Practice Guidelines of management of liver cancer (EASL-EORTC). He is President of the AASLD-SIG of Hepatobiliary neoplasia. He has published more than 290 articles in peer-reviewed journals such as New England Journal of Medicine, Lancet, Nature Rev Clin Oncol, Nature, Nature Rev Dis Primers, Nature Genetics, JCO, Nature Reviews Gastroenterology & Hepatology, Lancet Oncology, Cancer Cell, Gastroenterology , J Hepatology and Nature Com (total citations 70,219, total impact factor 4,461; h index 118-Google Scholar), > 55 chapters of books, and has delivered more than 605 lectures. He is Senior Editor of Clinical Cancer Research. Of note, he has been recognized as Top-1% cited researcher in Clarivate Analytics since 2014-2019. 

Anthony El-Khoueiry

Richard Finn


Linking cancer drivers to targeted therapies in HCC
Open to view video.
Open to view video. Presenter: Jessica Zucman-Rossi
Mechanisms of action of drugs effective in HCC
Open to view video.
Open to view video. Presenter: Augusto Villanueva
New drugs effective in the systemic treatment of HCC
Open to view video.
Open to view video. Presenter: Josep Llovet
Advances in immunotherapy for HCC
Open to view video.
Open to view video. Presenter: Anthony El-Khoueiry
The place of novel therapies in the AASLD guidelines for HCC
Open to view video.
Open to view video. Presenter: Richard Finn
Panel Discussion/Q&A
Open to view video.
Open to view video.
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.